EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2011

Conditions
Breast Neoplasms
Interventions
DRUG

EndoTAG-1 + paclitaxel

EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly

DRUG

EndoTAG-1

EndoTAG-1 44 mg/m² twice weekly

DRUG

Paclitaxel

Paclitaxel 90 mg/m² weekly

Trial Locations (33)

1000

Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels

Unknown

CHU Brugmann, Brussels

UZ Antwerpen, Edegem

CHU Liège, Liège

Centre Oscar Lambret, Lille

Cente Antoine Lacassagne, Nice

Institut Curie, Paris

Hôpital de Jour Centre Henri Kaplan, Tours

Institut Gustave Roussy, Villejuif

Vedanta Institute of Medical Science, Ahmedabad

Bangalore Institute of Oncology, Bangalore

Searoc Cancer Center, Jaipur

Lakeshore Hospital, Kochi

Deenanath Mangeshkar Hospital, Pune

Kaushalya Medical Foundation, Thāne

Wojewodzkie Centrum Onkologii, Gdansk

Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Gliwice

Instytut im. M. Sklodowskiej-Curie, Lublin

NZOZ Grupowa Specjalistyczna, Olsztyn

Klinika Onkologii Adadmii Medycznej, Poznan

"Institute of Oncology Prof. Dr. Al. Trestioreanu", Bucharest

"Institute of Oncology Prof. Dr. I. Chiricuta", Cluj-Napoca

Center of Medical Oncology, Iași

Emergency County Hospital Sibiu, Sibiu

"Oncology Clinic Oncomed", Timișoara

Dnepropetrovsk State Medical Acedamy, Dnipro

Institute of Medical Radiology of Acedamy of Medical Sciences, Kharkiv

Department of Abdominal Surgery, Kiev

Institut of Oncology, Kiev

Surgical Department, Kiev

Rivne Regional Oncological Dispensary, Rivne

Sumy Reginal Oncology Center, Sumy

Regional Clinical Oncological Dispensary, Uzhhorod

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MediGene

INDUSTRY